ArticleHypertension (Dallas, Tex. : 1979)2019
Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia.
Article in Hypertension (Dallas, Tex. : 1979), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2026Pooled it
- Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.Ontario health technology assessment series · 2023Pooled it
- sFlt-1/PlGF ratio use does not reduce hospitalisation duration in suspected preeclampsia: the PRECOG study, a multicentre randomised trial.Scientific reports · 2025Trial
- Hypertensive disorders of pregnancy and women's health throughout the life course: an update review 2025-2026.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations.Journal of the American Society of Nephrology : JASN · 2026Review
- Effect of prophylactic subcutaneous unfractionated heparin on the maternal sFlt-1/PlGF ratio: a retrospective cohort study.BMC pregnancy and childbirth · 2026Article
- Preeclampsia: Contemporary Concepts in Pathophysiology, Risk Stratification, Prevention and Monitoring.Journal of clinical medicine · 2026Review
- Angiogenic Biomarkers and Neonatal Outcomes in Suspected Preeclampsia: Retrospective Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- Clinical Deployment of Interpretable AI: Bridging Routine Clinical Tests and Proteomic Signatures for Preeclampsia Risk Stratification.Current drug targets · 2026Article
- The placental maturation inflection point: an integrative biological framework for understanding early-onset versus late-onset preeclampsia.Frontiers in endocrinology · 2026Review
- Divergent Blood Pressure Thresholds in Hypertensive Disorders of Pregnancy: A Narrative Review of Global Guideline Discordance and Clinical Implications.International journal of hypertension · 2026Article
- Short-term preeclampsia prediction: cutoff variations for sFlt-1/PlGF in U.S. Patients with or without hypertensive disorders.Annals of medicine · 2025Article
- Elevated sFlt-1/PlGF ratio in women with suspected or confirmed early-onset preeclampsia and super-imposed preeclampsia complicated by HELLP syndrome as well as abnormal umbilical artery Doppler findings and non-reassuring fetal status requiring immediate delivery: a prospective cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Placenta-Derived Proteins in Preeclampsia: A Human In Vivo Study.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Late vs. Early Preeclampsia.International journal of molecular sciences · 2025Review
- Article
- Comment on "Predictive accuracy of sFlt-1/PlGF ratio for preeclampsia and adverse outcomes: prospective, multicenter including primary, secondary, and tertiary care institutions, observational study in Japan".Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- sFlt-1/PlGF ratio thresholds for diagnosing pre-eclampsia in pregnant women with high blood pressure.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Observational
- The Role of Angiogenetic Factors in Preeclampsia.International journal of molecular sciences · 2025Review
- Predictive accuracy of sFlt-1/PlGF ratio for preeclampsia and adverse outcomes: prospective, multicenter including primary, secondary, and tertiary care institutions, observational study in Japan.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Observational
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current diagnostic criteria have limited clinical value for prediction of preeclampsia and fetal adverse outcomes. The prediction of short-term outcome in pregnant women with suspected preeclampsia study in Asia (PROGNOSIS Asia) was a prospective, multicenter study designed to investigate the value of the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio for predicting adverse outcomes in pregnant Asian women with suspected preeclampsia. Seven hundred sixty-four pregnant women at gestational week 20+0 days (18+0 days in Japan) to 36+6 days were enrolled at 25 sites in Asia. The primary objectives were to demonstrate the value of the sFlt-1/PlGF ratio for ruling out preeclampsia within 1 week and ruling in preeclampsia within 4 weeks. The value of the ratio for predicting fetal adverse outcomes was also assessed. Seven hundred patients were evaluable for primary end point analysis. The prevalence of preeclampsia was 14.4%. An sFlt-1/PlGF ratio of ≤38 had a negative predictive value of 98.6% (95% CI, 97.2%-99.4%) for ruling out preeclampsia within 1 week, with 76.5% sensitivity and 82.1% specificity. The positive predictive value of a ratio of >38 for ruling in preeclampsia within 4 weeks was 30.3% (95% CI, 23.0%-38.5%), with 62.0% sensitivity and 83.9% specificity. An sFlt-1/PlGF ratio of ≤38 had a negative predictive value of 98.9% (95% CI, 97.6%-99.6%) for ruling out fetal adverse outcomes within 1 week and a ratio of >38 had a positive predictive value of 53.5% (95% CI, 45.0%-61.8%) for ruling in fetal adverse outcomes within 4 weeks. The sFlt-1/PlGF ratio cutoff of 38 demonstrated clinical value for the short-term prediction of preeclampsia in Asian women with suspected preeclampsia, potentially helping to prevent unnecessary hospitalization and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.